News Highlight Ractigen Announces First Patient Dosed in the Phase I Clinical Trial of RAG-01 for NMIBC JIANGSU, China, April 3, 2024 – Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutics,…ractigenApril 3, 2024
News Highlight Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Jiangsu, China — Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA)…ractigenMarch 3, 2023